All In Biotech

Drug Trial Radar · NCT02100046

Assessment of the Effectiveness of Ethosuximide in the Treatment of Peripheral Neuropathic Pain.

Last checked: Nov 20, 2026Latest source record: Apr 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 114 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

114

Actual

Start

Mar 2014

Primary completion

Sep 2016

Study completion Jan 1, 2017

Sponsor

Lead sponsor
University Hospital, Clermont-FerrandAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Fondation Apicil
First posted
Mar 31, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Currently, it is established that the voltage-gated calcium channels modulate pain perception due to an influence on the neuronal transmission and excitability. In the past, attention has focused on the modulation of high voltage activated calcium channel. More recently, scientific interest has proven to the low voltage activated calcium channel, also called T-type channels. The data from the literature show significant involvement of these channels in the physiology of nociception and pathophysiology of acute and chronic pain. Moreover, in several animal pain models (acute, neuropathic, inflammatory), T-type channels inhibition alleviates painful behaviours. Analgesics treatments available in clinic are ineffective in some patients with chronic pain (neuropathic, inflammatory) and often induce deleterious side effects. Thus, the clinical use of selective inhibitors of T-type channels could not only help the development of new therapies for the treatment of neuropathic pain (prevalence = 5-8 %), but also have a pharmaco-economic impact due to the low selling price of their inhibitor currently available: Zarontin®. The purpose of this study is to assess the effectiveness of ethosuximide (Zarontin®) on the pain symptoms and quality of life in patients with peripheral neuropathic pain compared to a control group.

Conditions

  • Neuropathic Traumatic Pain
  • Pain NRS ≥ 4
  • Peripheral Neuropathic Pain
  • Neuropathic Pain Diagnostic Questionnaire (DN4) ≥ 4

Interventions

  • Zarontin® (ethosuximide) and Stodal®Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Assessment of the analgesic efficacy of ethosuximide in peripheral neuropathic pain patientsTime frame: day 43

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • CHU de Clermont-Ferrand

    Clermont-Ferrand, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.